Company Performance Metrics
GenomixIQ is the first autonomous AI platform purpose-built for clinical genomics, built by Ambharii Labs.
The problem - Clinical genetics labs spend 60 to 90 minutes classifying a single genetic variant that is deterministic and solvable. A mid-size lab burns significant dollars per month on manual variant classification.
The platform: 12
autonomous AI agents run in parallel across variant classification, clinical reporting, trial matching, pharmacogenomics, somatic oncology, rare disease, hereditary cancer, and drug discovery. All governed by G-ARVIS.
Key differentiators:
8 seconds per variant versus 60 to 90 minutes manual.
Zero hallucinations: G-ARVIS Safety Gate blocks any Pathogenic classification without a verified citation. Architectural enforcement, not prompting. FHIR R4 native: DiagnosticReport output for Epic and Cerner ready day one, not a roadmap item. G-ARVIS composite score 0.937. Clinical grade threshold 0.90. Passed.
ARGUS autonomous correction engine. 87.3% error recovery rate. Open-core: pip install argus-ai.
Any-cloud or on-premises Kubernetes. Single-command deploy. HIPAA-ready. PHI tokenization before any LLM prompt.
Clinical coverage: Hereditary Cancer including BRCA1/2 and Lynch syndrome across 80 plus genes. Pharmacogenomics across 300 plus CPIC drug-gene pairs. Somatic Oncology with TMB, MSI-H, and OncoKB therapy matching. Rare Disease with trio analysis and de novo detection. Drug Discovery with ADMET prediction and target validation.
API live and publicly testable at api.genomixiq.com/docs. Design partner program open at genomixiq.com. Acquisition conversations open at anil@ambharii.com.
Parent organization: Ambharii Labs. Founded by Anil Prasad, 28 years of production AI. Top 100 AI Leaders USA 2024.
